Frequency Screening Should Not Function As De Facto Denial Of Payment
This article was originally published in The Gray Sheet
Medicare claims for clinical laboratory tests identified during frequency screening should not automatically be denied, members of the Health Care Financing Administration's Negotiated Rulemaking Committee for clinical laboratory diagnostic tests concurred at an Aug. 26 meeting in Washington, D.C.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”